[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ataraxis AI, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100647282","ataraxis-real-world-clinical-outcomes-registry-linking-ai-based-pathology-scores-to-patient-outcomes-100647282",false,"NCT07706842","Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes","Ataraxis Real-World Clinical Outcomes: A Prospective, Multi-Site, Observational Registry Linking AI-Based Pathology Scores With Short- and Long-Term Outcomes","ARC","Inclusion Criteria:\n\n* Aged 18 years or older at the time of consent.\n* Diagnosis of a solid tumor malignancy, confirmed histologically or cytologically.\n* Patient is undergoing Ataraxis testing as part of their routine clinical care.\n* Availability of a pathology specimen.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent.\n* Patient for whom an Ataraxis test result was not successfully generated (e.g., due to sample quality, technical failure, or any reason resulting in a non-reportable result).","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will link Ataraxis test results with short- and long-term patient outcomes to evaluate the real-world performance and clinical utility of Ataraxis tests. The ARC Registry utilizes an adaptable design, where additional Sponsor-led analyses and investigator-initiated ancillary studies can be added after the initial study is opened.",[26,27],"Solid Tumor Malignancy","Breast Cancer",[29,30,31,32],"breast cancer","artificial intelligence","registry","digital pathology","NOT_YET_RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-16","ACTUAL",{"date":39,"type":21},"2026-07-31",{"date":41,"type":21},"2038-12",{"name":43,"class":44},"Ataraxis AI, Inc.","INDUSTRY",""]